Allen Institute’s big new bet: $200M effort aims to go from mapping the brain to treating disease

The Allen Institute, established by the late Microsoft co-founder Paul Allen, is launching a $200 million initiative called the Brain Health Accelerator to develop gene therapies for neurodegenerative diseases. The program, based in Seattle, will focus on diseases like Alzheimer’s, Parkinson’s, Huntington’s, and ALS, marking the first time the institute will shift from brain research to direct disease treatment. Funding for the accelerator comes from the Fund for Science and Technology, created by Allen’s estate with a $3.1 billion endowment. The initiative will also rely on federal grants, including support from the National Institutes of Health (NIH). Over 14 years, the project will expand from nearly 60 employees to 200, with plans to grow funding through partnerships. The accelerator builds on the institute’s two decades of brain-mapping research, using advances in single-cell genomics to catalog thousands of brain cell types. This high-resolution mapping allows researchers to identify genetic switches in specific cells, enabling targeted gene therapies for affected circuits. Ed Lein, executive vice president of the Allen Institute, stated the goal is to develop therapies that target disease-affected cells rather than proteins. The initiative aims to begin clinical trials within five years, with ALS identified as a potential early focus due to its well-understood cellular targets. The collaboration with NIH ensures public access to research data, creating a hybrid public-private partnership. Lein emphasized that while the institute could operate independently, federal funding accelerates progress by scaling infrastructure and research.